Daily Cardiology Research Analysis
Analyzed 172 papers and selected 3 impactful papers.
Summary
Analyzed 172 papers and selected 3 impactful articles.
Selected Articles
1. Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
In this phase 3 randomized trial in adults with type 1 diabetes and CKD, finerenone produced a 25% greater reduction in urinary albumin-to-creatinine ratio over 6 months versus placebo. Hyperkalemia was more frequent with finerenone but rarely led to discontinuation.
Impact: This is the first phase 3 RCT to demonstrate albuminuria lowering with finerenone in type 1 diabetes CKD, extending benefits beyond type 2 diabetes and informing cardio-renal risk reduction strategies.
Clinical Implications: Finerenone may become a therapeutic option to reduce albuminuria in type 1 diabetes with CKD, with monitoring for hyperkalemia. Outcomes trials are needed to confirm effects on hard renal and cardiovascular endpoints.
Key Findings
- Finerenone reduced urinary albumin-to-creatinine ratio by 34% over 6 months versus 12% with placebo.
- Geometric mean ratio for finerenone vs placebo was 0.75 (95% CI, 0.65–0.87; P<0.001), indicating a 25% greater reduction.
- Hyperkalemia occurred in 10.1% with finerenone vs 3.3% with placebo; 1.7% discontinued due to hyperkalemia.
Methodological Strengths
- Phase 3 randomized, placebo-controlled design
- Clinically relevant, quantifiable primary endpoint (albuminuria) with prespecified 6-month assessment
Limitations
- Short follow-up (6 months) and surrogate primary endpoint (albuminuria) rather than hard outcomes
- Modest sample size may limit power for safety and subgroup analyses
Future Directions: Larger, longer-term trials in type 1 diabetes should evaluate renal and cardiovascular outcomes, optimal monitoring strategies for hyperkalemia, and integration with existing RAAS blockade and SGLT2 inhibitors.
BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown. METHODS: We conducted a phase 3 trial involving adults who had type 1 diabetes, CKD (estimated glomerular filtration rate [eGFR], 25 to <90 ml per minute per 1.73 m RESULTS: A total of 242 participants underwent randomization. The median urinary albumin-to-creatinine ratio decreased from 574.6 at baseline to 373.5 at 6 months among all the participants assigned to receive finerenone and from 506.4 to 475.6 among those assigned to receive placebo. Over a period of 6 months, the urinary albumin-to-creatinine ratio decreased by 34% with finerenone (geometric mean ratio to baseline, 0.66; 95% confidence interval [CI], 0.60 to 0.73) and 12% with placebo (geometric mean ratio to baseline, 0.88; 95% CI, 0.79 to 0.98), which corresponded to a 25% greater reduction with finerenone than with placebo (geometric mean ratio for finerenone vs. placebo, 0.75; 95% CI, 0.65 to 0.87; P<0.001). The most common adverse event was hyperkalemia (in 12 participants [10.1%] with finerenone and in 4 [3.3%] with placebo); 2 participants (1.7%) discontinued finerenone because of hyperkalemia. At 6 months, the change in the eGFR was -5.6 ml per minute per 1.73 m CONCLUSIONS: In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).
2. Hyodeoxycholic acid attenuates atherosclerosis by antagonizing FXR and modulating the PD-1/mTORC1 signaling axis.
Serum HDCA levels are reduced in patients with atherosclerosis, and exogenous HDCA curbs plaque growth in vivo by antagonizing FXR and reprogramming Treg metabolism via the PD-1/mTORC1 pathway. The work identifies ZNF671 as a migration-restricting factor relieved by HDCA, positioning the HDCA–FXR–PD-1/mTORC1 axis as a therapeutic immunometabolic target.
Impact: This study uncovers a mechanistically coherent immunometabolic pathway linking bile acid signaling to Treg function and plaque biology, opening a new therapeutic avenue beyond lipid lowering.
Clinical Implications: While preclinical, targeting the HDCA–FXR–PD-1/mTORC1 axis may enable therapies that enhance Treg trafficking and effector functions to stabilize or regress plaques, complementing lipid-lowering strategies.
Key Findings
- Serum HDCA is significantly reduced in patients with atherosclerosis.
- Systemic HDCA therapy attenuates plaque burden in vivo in ApoE-deficient mice.
- HDCA-treated Tregs reduce lesion growth; FXR-deficient Tregs fail to confer benefit, indicating FXR dependence.
- HDCA antagonizes FXR and modulates PD-1/mTORC1 signaling to reprogram Treg metabolism, shifting from CPT1a-driven fatty acid oxidation toward glycolysis and increased ATP.
- ZNF671 is identified as a transcriptional inhibitor of Treg migration that is mitigated by HDCA-dependent metabolic switching.
Methodological Strengths
- Integration of human patient data with in vivo ApoE−/− models and mechanistic Treg adoptive transfer experiments
- Multi-layer pathway interrogation (FXR antagonism, PD-1/mTORC1 signaling, metabolic flux, transcriptional regulation)
Limitations
- Predominantly preclinical with limited quantification of human cohort size and outcomes
- Translational uncertainties regarding HDCA dosing, safety, and long-term effects
Future Directions: Quantify HDCA levels and outcomes in larger human cohorts; develop selective FXR-modulatory or HDCA-mimetic agents; and test plaque-stabilizing efficacy and safety in early-phase clinical trials.
Accumulating evidence suggested that bile acids play a significant role in modulating metabolic and inflammatory diseases. In this study, we investigated the roles of the farnesoid X receptor (FXR) and its endogenous antagonist hyodeoxycholic acid (HDCA) in the development of atherosclerosis (AS). We found that serum HDCA was significantly reduced in patients with AS, and systemic HDCA therapy attenuated plaque burden in vivo. Adoptive transfer of HDCA-treated Foxp3+ Tregs into ApoE-deficient recipients reduced lesion growth, whereas FXR-deficient Tregs failed to confer benefit. HDCA enhanced Treg migration and accumulation within plaques and reprogrammed Treg metabolism by antagonizing FXR and modulating PD-1/mTORC1 signaling. This shift relieved CPT1a-driven fatty acid oxidation bias, increased glycolysis and ATP production, and improved migratory capacity and effector function. We further identify ZNF671 as a transcriptional inhibitor of Treg migration that is mitigated by HDCA-dependent metabolic switching. Collectively, HDCA reduced FXR-mediated metabolic constraints while activating glycolytic and migratory programs in Tregs, thereby improving lipid handling and immune regulation within the plaque microenvironment. These findings position the HDCA-FXR-PD-1/mTORC1 axis as a novel immunometabolic target for AS.
3. Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study.
In a multicenter, randomized, double-blind, placebo-controlled phase 2 trial of 118 post-MI patients with frequent PVCs, varenicline reduced PVC burden by 60.1 percentage points versus placebo, doubled the responder rate, and lowered nonsustained VT incidence, without proarrhythmic signals.
Impact: This trial introduces cardiac nAChRs as a novel antiarrhythmic target and demonstrates clinically meaningful PVC/NSVT reductions with an approved drug, opening a new therapeutic avenue beyond ion-channel blockers.
Clinical Implications: If validated in larger outcome trials, varenicline could become an off-label or repurposed option to reduce ventricular ectopy post-MI, particularly when conventional antiarrhythmics are contraindicated or poorly tolerated.
Key Findings
- Varenicline achieved a 60.1 percentage point greater reduction in 24-hour PVC burden vs placebo (95% CI 21.3–98.8; P=0.001).
- Responder rate (≥50% PVC reduction) was higher with varenicline: 67.8% vs 30.5% (RR 2.22; 95% CI 1.46–3.39; P<0.0001).
- Nonsustained VT incidence was lower with varenicline: 20.3% vs 37.3% (RR 0.49; 95% CI 0.29–0.85; P=0.007); no deaths or malignant VAs occurred.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled design
- Objective arrhythmia quantification using 72-hour ambulatory ECG monitoring
Limitations
- Phase 2 sample size and short treatment duration (45 days) limit generalizability and long-term safety inference
- Clinical outcome effects (eg, mortality, hospitalization) were not assessed
Future Directions: Conduct phase 3 trials powered for clinical outcomes, delineate dose-response and safety across comorbid populations, and explore mechanism via cardiac nAChR engagement biomarkers.
BACKGROUND: Conventional antiarrhythmic drugs that target cardiac ion channels carry proarrhythmic risks, highlighting the need for alternative therapeutic approaches. Cardiac nicotinic acetylcholine receptors (nAChRs) represent a novel electrophysiological target. OBJECTIVES: The aim of this exploratory, proof-of-concept phase 2 trial was to evaluate the effect of varenicline, a partial nAChR agonist, on frequent premature ventricular complexes (PVCs) after myocardial infarction (MI) and to assess its short-term safety and biological target engagement. METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, adults with frequent PVCs (≥1,000/24 h) assessed using 72-hour ambulatory electrocardiographic monitoring at ≥4 weeks post-MI were randomly assigned (1:1) to varenicline 0.5 mg twice daily or matching placebo for 45 days, in addition to guideline-directed medical therapy. The primary endpoint was the percentage change in 24-hour PVC count from baseline to week 6. Key secondary endpoints included responder rate (≥50% reduction in PVC count) and the incidence of nonsustained ventricular tachycardia (VT). RESULTS: Among 118 randomized patients, varenicline produced a 60.1 percentage point greater reduction in PVC burden compared with placebo (95% CI: 21.3-98.8 percentage points; P = 0.001). The responder rate was higher with varenicline (67.8% vs 30.5%; RR: 2.22; 95% CI: 1.46-3.39; P < 0.0001), and nonsustained VT incidence was lower (20.3% vs 37.3%; RR: 0.49; 95% CI: 0.29-0.85; P = 0.007). No deaths or malignant ventricular arrhythmias occurred in the varenicline group, with comparable adverse event rates between groups. CONCLUSIONS: In this phase 2 trial, varenicline significantly reduced PVC burden and nonsustained VT incidence in post-MI patients without evidence of a proarrhythmic effects. These findings support cardiac nAChRs as a potential antiarrhythmic target and justify further evaluation in larger outcome-driven trials. (Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial [Var-PVC]; NCT06780215).